The LeVe CPAP System for Oxygen-Efficient CPAP Respiratory Support: Development and Pilot Evaluation.
The LeVe CPAP System for Oxygen-Efficient CPAP Respiratory Support: Development and Pilot Evaluation.
复制标题
DOI：
10.3389/fmedt.2021.715969
复制
发表时间：
2021
影响因子：
--
通讯作者：
Kapur N
中科院分区：
文献类型：
--
作者：
Culmer P;Davis Birch W;Waters I;Keeling A;Osnes C;Jones D;de Boer G;Hetherington R;Ashton S;Latham M;Beacon T;Royston T;Miller R;Littlejohns A;Parmar J;Lawton T;Murdoch S;Brettle D;Musasizi R;Nampiina G;Namulema E;Kapur N
背景资料：由严重急性呼吸道综合征冠状病毒2型（SARS-CoV-2）引起的COVID-19大流行对医疗保健提供者（HCP）提出了重大要求，要求他们为中度至重度症状的患者提供呼吸支持。持续气道正压通气（CPAP）无创通气可以帮助中度症状的患者避免重症监护中的有创通气。然而，现有的CPAP系统可能是复杂的（并且因此是昂贵的）或需要高水平的氧气，限制了它们在资源紧张的环境中的使用。技术开发+测试：LeVe（“Light”）CPAP系统的开发采用了节约创新的原则，以产生低复杂性和高资源效率的解决方案。LeVe系统利用电风扇鼓风机的空气流动动力学，电风扇鼓风机固有地适合于以适当的流速为CPAP输送正压。实验室评价表明，LeVe系统的性能与用于输送CPAP的其他市售系统等同，在2.4% RMS误差内实现10 cm H2O目标压力，并根据来自商业浓缩器的10 L/min氧气实现50-70% FiO 2。试点评估：在乌干达坎帕拉的Mengo医院，对LeVe CPAP系统进行了测试，以评价其安全性和可接受性。该研究表明，该系统可以安全使用，不会引起缺氧或高碳酸血症，并且用户对其使用的耐受性良好，未报告不良事件。结论：为了为COVID-19大流行相关的大量患者提供呼吸支持，医疗保健提供商需要资源高效的解决方案。我们已经证明，这可以通过CPAP通气系统的简单工程来实现，该系统使用安全并且在健康志愿者中耐受良好。这种方法也可能有益于其他呼吸系统疾病，这些疾病在低收入和中等收入国家（LMIC）中往往得不到解决，因为缺乏针对有限氧气资源设计的适合环境的技术。
Background: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a significant demand on healthcare providers (HCPs) to provide respiratory support for patients with moderate to severe symptoms. Continuous Positive Airway Pressure (CPAP) non-invasive ventilation can help patients with moderate symptoms to avoid the need for invasive ventilation in intensive care. However, existing CPAP systems can be complex (and thus expensive) or require high levels of oxygen, limiting their use in resource-stretched environments. Technical Development + Testing: The LeVe (“Light”) CPAP system was developed using principles of frugal innovation to produce a solution of low complexity and high resource efficiency. The LeVe system exploits the air flow dynamics of electric fan blowers which are inherently suited to delivery of positive pressure at appropriate flow rates for CPAP. Laboratory evaluation demonstrated that performance of the LeVe system was equivalent to other commercially available systems used to deliver CPAP, achieving a 10 cm H2O target pressure within 2.4% RMS error and 50–70% FiO2 dependent with 10 L/min oxygen from a commercial concentrator. Pilot Evaluation: The LeVe CPAP system was tested to evaluate safety and acceptability in a group of ten healthy volunteers at Mengo Hospital in Kampala, Uganda. The study demonstrated that the system can be used safely without inducing hypoxia or hypercapnia and that its use was well-tolerated by users, with no adverse events reported. Conclusions: To provide respiratory support for the high patient numbers associated with the COVID-19 pandemic, healthcare providers require resource efficient solutions. We have shown that this can be achieved through frugal engineering of a CPAP ventilation system, in a system which is safe for use and well-tolerated in healthy volunteers. This approach may also benefit other respiratory conditions which often go unaddressed in Low and Middle Income Countries (LMICs) for want of context-appropriate technology designed for the limited oxygen resources available.
登录
查看更多内容
影响因子：
3.7
作者：
Alviset S;Riller Q;Aboab J;Dilworth K;Billy PA;Lombardi Y;Azzi M;Ferreira Vargas L;Laine L;Lermuzeaux M;Mémain N;Silva D;Tchoubou T;Ushmorova D;Dabbagh H;Escoda S;Lefrançois R;Nardi A;Ngima A;Ioos V
通讯作者：
Ioos V
影响因子：
2.5
作者：
Kallet, Richard H.
通讯作者：
Kallet, Richard H.
影响因子：
3.1
作者：
Garzotto, Francesco;Ceresola, Erica;Opocher, Giuseppe
通讯作者：
Opocher, Giuseppe
影响因子：
3.4
作者：
Cavallo, Leonardo;Marciano, Antonia;Oteri, Giacomo
通讯作者：
Oteri, Giacomo
影响因子：
2.5
作者：
Bennett, Desmond J.;Carroll, Ryan W.;Kacmarek, Robert M.
通讯作者：
Kacmarek, Robert M.